# V1: robot model

Canonical ID: `e6527aa8-0ffa-42a7-9edb-837f1575ad96`

- **Slug:** vicarious-v1
- **Form factor:** surgical
- **Maturity stage:** research
- **Lifecycle:** active
- **Deployments registered:** 0

## Specs

- **notes:** [object Object],[object Object],[object Object],[object Object]
- **products:** V1: single-port system with a '9-DoF human-like' instrument and an immersive VR-style surgeon interface ('transport the surgeon inside the patient'). Pre-commercial; no FDA submission yet.
- **formFactor:** surgical (single-port surgical robot concept: 9-DoF human-like instrument + immersive VR-style surgeon interface)

## Deployments

_No deployments registered for this model._

## Supply chain

_No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model's suppliers._

_Suppliers appear when verified with at least two strong sources. Sources are append-only; corrections add new sources rather than rewrite history._

## Common questions

### What is V1?

Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.

### Who makes V1?

V1 is made by Vicarious Surgical, based in Waltham, Massachusetts, USA, founded in 2014.

### Where is V1 deployed?

No verified deployments of V1 are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.

### What is V1's maturity stage?

V1 is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.


## Sources (4)

1. https://www.businesswire.com/news/home/20260303-vicarious-surgical-nyse-delisting
2. https://www.therobotreport.com/vicarious-surgical-faces-nyse-delisting-again/
3. https://www.massdevice.com/vicarious-surgical-timeline-delay/
4. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=RBOT

_API: GET /v1/models/e6527aa8-0ffa-42a7-9edb-837f1575ad96 · canonical URL: /models/vicarious-v1_